Who are Epinephrin 0.07's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epinephrin 0.01, Ephedrine, bolus, IM epinephrine 1:1000, Ephedrine-S, Racemic adrenaline, cardiac output changes with "ephedrine".

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epinephrin-0-07.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Epinephrin 0.07 — Competitive Intelligence Brief

Epinephrin 0.07 (Epinephrin 0.07) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine; adrenergic agonist. Area: Emergency medicine; Cardiovascular; Respiratory.

marketed Catecholamine; adrenergic agonist Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors Emergency medicine; Cardiovascular; Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Epinephrin 0.07 (Epinephrin 0.07) — Kasr El Aini Hospital. Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Epinephrin 0.07 TARGET	Epinephrin 0.07	Kasr El Aini Hospital	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Epinephrin 0.01	Epinephrin 0.01	Kasr El Aini Hospital	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Ephedrine, bolus	Ephedrine, bolus	University of Parma	marketed	Sympathomimetic amine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
IM epinephrine 1:1000	IM epinephrine 1:1000	University of Louisville	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Ephedrine-S	Ephedrine-S	Dalian Municipal Central Hospital	marketed	Sympathomimetic amine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Racemic adrenaline	Racemic adrenaline	Oslo University Hospital	marketed	Sympathomimetic amine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
cardiac output changes with "ephedrine"	cardiac output changes with "ephedrine"	University Tunis El Manar	marketed	Sympathomimetic amine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine; adrenergic agonist class)

Kasr El Aini Hospital · 2 drugs in this class
Aga Khan University · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Ministry of Health, Spain · 1 drug in this class
University of Louisville · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epinephrin 0.07 — Competitive Intelligence Brief. https://druglandscape.com/ci/epinephrin-0-07. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab